Prognostic markers for CLL - how do they help determine who gets which treatment?
Overview of RESONATE-2 clinical trial of ibrutinib in CLL
John Gribben et al.
CLL therapy - current status and issues
Potential concerns with ventoclax and Richter's transformation
Discussion of a Phase III trial evaluating the efficacy and safety of idelalisib